Skip to main content

Table 2 Cox uni- and multivariate analysis of recurrence free and overall survival according to RBM3 mRNA levels (Cohort I) and protein expression (Cohort II)

From: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer

 

Recurrence free survival

  

Overall survival

  
  

HR (95% CI)

 

p-value

 

HR (95% CI)

 

p-value

Cohort I

        
   

Univariate

   

Univariate

 

low

(n = 115, nevent = 85)

1.00

  

(n = 115, nevent = 54)

1.00

  

high

(n = 142, nevent = 89)

0.64 (0.47-0.86)

 

0.003

(n = 139, nevent = 50)

0.64 (0.44-0.95)

 

0.024

   

Multivariate

   

Multivariate

 

low

(n = 103, nevent = 77)

1.00

  

(n = 103, nevent = 51)

1.00

  

high

(n = 119, nevent = 71)

0.61 (0.44-0.84)

 

0.003

(n = 117, nevent = 50)

0.62 (0.41-0.95)

 

0.028

Cohort II

        
       

Univariate

 

negative

x

x

x

x

(n = 74, nevent = 33)

1.00

  

positive

x

x

x

x

(n = 77, nevent = 44)

0.53 (0.35-0.79)

 

0.002

       

Multivariate

 

negative

x

x

x

x

(n = 68, nevent = 29)

1.00

  

positive

x

x

x

x

(n = 71, nevent = 42)

0.61 (0.40-0.92)

 

0.017

  1. Multivariate analysis included adjustment for age (continuous) stage (I-II vs III-IV), grade (I-II vs III) and residual disease (none vs any, only available for Cohort I).